Soleil Boughton Sells 3,458 Shares of Hims & Hers Health (NYSE:HIMS) Stock

Key Points

• Insider sale: Soleil Boughton sold 3,458 Hims & Hers shares for approximately $97,965 under a pre-arranged Rule 10b5-1 plan, reducing the insider’s position by 1.10% to 310,506 shares. Boughton previously sold 25,111 shares in August.
• Strong revenue but larger-than-expected loss: Second-quarter revenue rose 38.2% year over year to $753.21 million, beating estimates, while adjusted earnings missed expectations with a $0.37-per-share loss versus the anticipated $0.05 loss.
• Mixed outlook: Analysts maintain a consensus “Hold” rating with a $32.50 average price target. The company also faces regulatory and securities-litigation risks related to alleged consumer-data sharing and prescription practices, while institutional investors own 63.52% of the stock.

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) insider Soleil Boughton sold 3,458 shares of Hims & Hers Health stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $28.33, for a total transaction of $97,965.14. Following the completion of the sale, the insider owned 310,506 shares in the company, valued at approximately $8,796,634.98. This trade represents a 1.10% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Soleil Boughton also recently made the following trade(s):

• On Wednesday, August 19th, Soleil Boughton sold 25,111 shares of Hims & Hers Health stock. The stock was sold at an average price of $27.55, for a total transaction of $691,808.05.

Hims & Hers Health Price Performance

Shares of HIMS traded down $0.91 during mid-day trading on Thursday, hitting $27.77. 12,055,111 shares of the company were exchanged, compared to its average volume of 25,338,594. The stock has a market cap of $6.48 billion, a price-to-earnings ratio of -44.08 and a beta of 2.42. Hims & Hers Health, Inc. has a 1-year low of $13.74 and a 1-year high of $65.30. The company has a 50 day moving average of $31.89 and a 200-day moving average of $26.66. The company has a debt-to-equity ratio of 4.21, a quick ratio of 0.87 and a current ratio of 0.93.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.32). Hims & Hers Health had a negative return on equity of 6.51% and a negative net margin of 5.51%.The firm had revenue of $753.21 million during the quarter, compared to analyst estimates of $698.90 million. During the same quarter in the previous year, the firm posted $0.17 earnings per share. The company's quarterly revenue was up 38.2% on a year-over-year basis.

Institutional Investors Weigh In On Hims & Hers Health

A number of large investors have recently made changes to their positions in HIMS. Corient Private Wealth LP increased its holdings in shares of Hims & Hers Health by 38.3% in the second quarter. Corient Private Wealth LP now owns 22,727 shares of the company's stock valued at $788,000 after purchasing an additional 6,288 shares during the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in Hims & Hers Health during the second quarter worth $1,030,000. California State Teachers Retirement System grew its holdings in Hims & Hers Health by 3,404.9% in the 2nd quarter. California State Teachers Retirement System now owns 8,000,068 shares of the company's stock valued at $277,362,000 after buying an additional 7,771,816 shares in the last quarter. Ameritas Advisory Services LLC grew its holdings in Hims & Hers Health by 12.8% in the 2nd quarter. Ameritas Advisory Services LLC now owns 17,965 shares of the company's stock valued at $623,000 after buying an additional 2,045 shares in the last quarter. Finally, Compass Financial Management LLC acquired a new stake in shares of Hims & Hers Health in the 2nd quarter worth $50,000. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts recently commented on the company. TD Cowen boosted their price target on Hims & Hers Health from $25.00 to $30.00 and gave the stock a "hold" rating in a research report on Tuesday, August 11th. Jefferies Financial Group set a $24.50 price objective on Hims & Hers Health in a report on Tuesday, May 12th. Zacks Research raised shares of Hims & Hers Health from a "strong sell" rating to a "hold" rating in a research note on Monday, July 13th. Weiss Ratings reaffirmed a "sell (d)" rating on shares of Hims & Hers Health in a report on Friday, August 7th. Finally, Wall Street Zen upgraded shares of Hims & Hers Health from a "sell" rating to a "hold" rating in a research report on Saturday, August 15th. Four research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $32.50.

Hims & Hers Health News Summary

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Hims raised its 2026 revenue outlook after second-quarter revenue increased 38.2% year over year to approximately $753 million, exceeding analysts’ expectations. Growth in weight-loss services, international markets and artificial-intelligence initiatives provides potential support for the long-term story. HIMS Raises 2026 Revenue Outlook as Q2 Sales Rise 38.2% Despite Loss
• Neutral Sentiment: Brokerage sentiment remains mixed, with HIMS receiving a consensus “Hold” rating. Analysts point to continued platform growth but also cite margin pressure and uncertainty surrounding FDA and regulatory matters. Hims & Hers Health Receives Consensus Rating of Hold
• Negative Sentiment: Multiple law firms announced or promoted securities class actions covering investors who purchased HIMS securities from August 4, 2025, through July 29, 2026. The lawsuits generally follow the stock’s sharp decline after the Federal Trade Commission’s complaint and allege that Hims made misleading statements or failed to disclose material risks. Investors have until November 2, 2026, to seek appointment as lead plaintiff. Kessler Topaz Announces HIMS Securities Fraud Class Action
• Negative Sentiment: The underlying allegations include sharing consumers’ protected health information with third-party advertising platforms and charging customers for prescriptions soon after intake, potentially before a meaningful provider consultation. Plaintiffs claim these practices could lead to regulatory scrutiny, penalties, legal expenses and reputational damage. The allegations have not been proven in court. Holzer & Holzer HIMS Investor Alert
• Negative Sentiment: Despite strong sales, Hims reported a second-quarter loss of $0.37 per share versus the consensus estimate of a $0.05 loss, while net loss and margin contraction highlighted the cost of funding rapid expansion. HIMS Raises 2026 Revenue Outlook Despite Loss

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients' doorsteps.

The company's product portfolio addresses key areas of men's and women's health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source